Clarus Ventures’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Clarus Ventures’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-4,644,705	Closed	-$8.04M	–	8
2015 Q4	$8.04M	Hold	4,644,705	–	–	5.63%	6
2015 Q3	$8.59M	Hold	4,644,705	–	–	4.94%	7
2015 Q2	$10.9M	Hold	4,644,705	–	–	4.78%	6
2015 Q1	$20.3M	Hold	4,644,705	–	–	8.46%	5
2014 Q4	$22.4M	Hold	4,644,705	–	–	6.39%	6
2014 Q3	$19.3M	Hold	4,644,705	–	–	7.71%	5
2014 Q2	$27.4M	Hold	4,644,705	–	–	9.71%	5
2014 Q1	$29.6M	Hold	4,644,705	–	–	8.57%	5
2013 Q4	$44.2M	Buy	+4,644,705	New	+$36.2M	12.5%	5

Other funds holding TLOG

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geneva Advisors Chicago, Illinois $5.81B AUM 23.71% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TSS

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Clarus Ventures's TLOG Position: Q1 2016 in Review

Clarus Ventures sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q1 2016, closing a stake of 4,644,705 shares — an estimated $8.04M sold.

Clarus Ventures first reported a position in TLOG in Q4 2013 and held it in 9 quarters. The position peaked at $44.2M in Q4 2013. 25 funds tracked by Wall St. Rank hold TLOG as of Q1 2016.

Clarus Ventures reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q1 2016 after selling out during the quarter.
Clarus Ventures sold 4,644,705 TetraLogic Pharmaceuticals Corporation shares in Q1 2016, an estimated $8.04M.
Clarus Ventures first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 9 quarters.
Clarus Ventures's TetraLogic Pharmaceuticals Corporation position peaked at $44.2M in Q4 2013.
25 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q1 2016.

Based on Clarus Ventures's 13F filing for Q1 2016, filed 22 Apr 2016.